June 15, 2020 - With much of the world focused on the immediacy of the COVID-19 pandemic, including its heavy human and economic toll, we have cast our eyes optimistically on the (near, we hope) future when companies regain sufficient confidence to re-enter the public M&A market in large numbers. Although...
Ipsen Acquires Clementia Pharmaceuticals for US$1.3 Billion
Davies acted for French biopharmaceutical company Ipsen in the acquisition of Québec-based Clementia Pharmaceuticals for a purchase price of US$25.00 per share in cash upfront, plus a contingent value right of US$6.00 per share, for a total transaction value of up to US$1.31 billion.
The acquisition, which includes Clementia’s key late-stage drug candidate palovarotene, is part of Ipsen’s transformative plan to boost its portfolio of products treating rare diseases.
The transaction closed on April 17, 2019, following approval of the plan of arrangement by Clementia shareholders and the Québec Superior Court.
The Davies team on this transaction included Bill Ainley, Brett Seifred, Emily Uza and Russell Hall (Corporate/M&A); Paul Lamarre (Tax); Jim Dinning and Alysha Manji-Knight (Competition); Jessica Bullock and Rachael Lee (Labour and Employment).
Mar. 23, 2020 - The COVID-19 pandemic has had, and is likely to continue to have, a major impact on the global economy as countries implement various levels of “social distancing” and other restrictions on normal activities. In these uncertain times, many businesses may find themselves reviewing their contracts...